Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds are provided according to Formula (I), and hydrates thereof, and compositions thereof; and methods of using and making the same. Compounds of the present invention are contemplated useful for suppressing pain during cosmetic, medical, and dental procedures. In another aspect, provided herein is a composition comprising the compound of Formula (I) or hydrate thereof and a pharmaceutically acceptable carrier.

An object of the present invention is to provide a compound or a salt thereof constituting lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids, and to provide lipid particles that can achieve a high nucleic acid encapsulation rate and excellent delivery of nucleic acids. According to an aspect of the present invention, a compound represented by Formula (1) or a salt thereof is provided.

##STR00001##

In the formula, X represents NR.sup.1 or O, R.sup.1 represents a hydrogen atom, a hydrocarbon group, or the like, R.sup.2 and R.sup.3 each independently represent a hydrogen atom, a hydrocarbon group, or the like, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, R.sup.11, and R.sup.12 each independently represent a hydrogen atom or an alkyl group, groups in any one or more pairs among R.sup.4 and R.sup.5, R.sup.10 and R.sup.5, R.sup.5 and R.sup.12, R.sup.4 and R.sup.6, R.sup.5 and R.sup.6, R.sup.6 and R.sup.7, R.sup.6 and R.sup.10, R.sup.12 and R.sup.7, and R.sup.7 and R.sup.8 may be linked to each other to form a 4- to 7-membered ring which may contain an O atom, a, b, c, and d are each independently represent an integer of 0 to 3, a+b is equal to or greater than 1, and c+d is equal to or greater than 1.

The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

A novel cationic lipid has a structure as represented by general formula (1) and specifically relates to a nitrogen-branched cationic lipid, and a liposome containing the cationic lipid, and a nucleic-acid pharmaceutical composition containing the liposome, a preparation method and application thereof, wherein, the definition of each symbol in the formula (1) is as defined herein. The cationic liposome containing the cationic lipid as represented by formula (1) can improve the loading rate and transport efficiency of nucleic-acid drugs. The formulation of the cationic liposome nucleic-acid pharmaceutical composition has good cell compatibility and higher gene transfection capability, and can improve the treatment and/or prevention effects of nucleic-acid drugs.

The present invention relates to a method for synthesizing ionic liquids comprising a carbonate functional group characterized in that it comprises a step of reaction A without addition of lithium between a first reactant selected among an imidazolium, a pyrrolidinium or an ammonium and a second reactant being a methyl formate imidazolium. The first reactant is an imidazolium alcohol, a pyrrolidinium alcohol or an ammonium alcohol salt, the anion of which is NTf2. The second reactant is a chloromethyl formate imidazolium. The application of this method will be found in the field of green chemistry and more specifically in the production of ionic liquids which can be used in lithium batteries with a graphite electrode.

The present invention relates to a method for synthesizing ionic liquids comprising a carbonate functional group characterized in that it comprises a step of reaction A without addition of lithium between a first reactant selected among an imidazolium, a pyrrolidinium or an ammonium and a second reactant being a methyl formate imidazolium. The first reactant is an imidazolium alcohol, a pyrrolidinium alcohol or an ammonium alcohol salt, the anion of which is NTf2. The second reactant is a chloromethyl formate imidazolium. The application of this method will be found in the field of green chemistry and more specifically in the production of ionic liquids which can be used in lithium batteries with a graphite electrode.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.